---
document_datetime: 2025-05-15 16:39:35
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/inomax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: inomax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.3774233
conversion_datetime: 2025-12-19 23:38:51.419903
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## INOmax

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,please alsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc. Article 61(3) - | 15/05/2025                          |                                          | PL                              |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(Package Leaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000269511                         | Update of the package leaflet with the additionofcontactdetailsoflocal representatives.                                                                                                                                                                                                                                                                               |            |             |                                                                                                                                                                                                                                              |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000256526 | C.1.3Change(s)intheSummary ofProduct Characteristics, Labelling or Package Leaflet of humanmedicinalproducts intended to implementtheoutcomeofaprocedure conceming PSUR or PASS, or the outcome of theassessmentdonebythecompetent authority under Articles 45 or 46 of Regulation1901/2006-C.1.3.a Implementationofwording agreedbythe competent authority -Accepted | 27/03/2025 | SmPC and PL | To update section 4.4 of the SmPC and section 2 of thePL toimplementthesignal recommendations on \"Nitric oxide - Pulmonary oedema in patients with veno-occlusive disease(EPITTno20086)'adopted at the 28 November 2024 at the PRAC meeting. |